Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

 
• By Bridget Silverman
  
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers